Generic rizatriptan (Maxalt) and sumatriptan (Imitrex)

March 27, 2013

The release of a generic substitute of the branded drug Imitrex (sumatriptan) has dramatically reduced the cost and improved the access to this uniquely effective migraine drug. The generic sumatriptan was released four years ago and now the price of one tablet is down to about $3 from over $20. The cost of two other generic triptans, Amerge (naratriptan) and Maxalt (rizatriptan) has remained very high, but it is expected to drop as more companies begin making generic copies. However, generics are not always the exact copies of the original branded drug that we expect them to be. In my previous post in 2009 I mentioned a study that showed that the generic Topamax (topiramate) does not work as well as the brand for some patients. I have also seen this with sumatriptan – my patients tell me that some generics do not work very well or at all. Out of about 10 generics of sumatriptan, I would guess that two are of poor quality. Once you find a generic that works for you, try to stick with the same generic manufacturer. The name of the manufacturer is printed on the bottle the pharmacy gives you. If one pharmacy does not have your generic, try another one. Here is a part of an email I just received from a patient (she gave me permission to share it with you):

“Just wanted to share with you that my pharmacy filled my maxalt melt prescription with yet another generic brand yesterday, which I found very unpleasant.

Previously the generic refills I’d gotten were from a company called PAR. The PAR pills resembled the original MAXALT melts in style of packaging (foil packets in plastic case) in taste and most important in melt-ability (never timed it but it always seemed to dissolve within 5 to 10 seconds–basically immediate dissolve)

But yesterday’s refill was from Mylan. These melts came in a regular prescription bottle of pills. I called the pharmacy after they were delivered thinking they accidentally gave me non-melts. They checked and told me, no, these were melts, just from a different company. They explained that this company (Mylan) packages them like any other pill (in bottles).

When I took the pill last night it felt like what i imagine it would feel like if you took a chewable vitamin and then waited for it to disintegrate in your mouth. It took minutes to “melt”, instead of seconds, and a grainy feeling remained even after that. it also made my upper palate sore, and tasted bad.

Today I called my pharmacist to double check that this was a melt and they checked again and it is. Luckily they were good enough to switch the rest of the prescription to the PAR generic brand. They also told me they would no longer carry the ones from Mylan. (They did say the Mylan generic is cheaper, though, so not sure how this will work out in the future.)”

Written by
Alexander Mauskop, MD
Continue reading
August 2, 2026
Alternative Therapies
A Wearable Device May ImproveBalance in Aging Adults and Possibly Vestibular Migraine
This technology uses imperceptible electrical stimulation delivered through electrodes placed behind the ears and on the upper neck. Early studies and pilot trials suggest improvements in balance and gait, with a favorable safety profile, but larger sham-controlled studies that measure actual falls, not just test performance, are still needed.
Read article
July 18, 2026
Alternative Therapies
Why Everyone Should Have Their Vitamin D Level Checked, And Why 'Normal' Isn't Good Enough
Vitamin D deficiency is common, often missed, and easy to correct. In this post I explain why “normal” lab values can be misleading, how vitamin D affects headaches, heart and brain health, and what levels and doses I recommend for my patients.
Read article
July 13, 2026
Brain disorders
fMRI-guidedTMS targeting improves outcomes
This post reviews new data showing that fMRI‑guided, connectivity‑based TMS targeting improves response rates in treatment‑resistant depression and likely other conditions. By mapping each patient’s brain circuits, clinicians can move beyond a one‑size‑fits‑all DLPFC target to condition‑specific and patient‑specific sites, a particularly important advance for migraine and network‑based pain disorders.
Read article
Insights from Dr. Alexander Mauskop on headaches and migraines
Subscribe to the Blog.
Subscribe
Subscribe